All In Biotech

Drug Trial Radar · NCT06838000

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

Last checked: Nov 20, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,268 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,268

Actual

Start

Feb 28, 2025

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 7 months, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and 6 to 17 YoA-years of age).

Conditions

  • Pneumococcal Infections

Interventions

  • PCV21Biological

    Investigational pneumococcal conjugate vaccine

  • 20vPCVBiological

    20-valent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting immediate adverse events (AEs)Time frame: Within 30 minutes post-vaccination
  2. Number of participants reporting solicited injection site and solicited systemic reactionsTime frame: Up to Day 7 post-vaccination
  3. Number of participants reporting unsolicited (spontaneously reported) injection site reactions and unsolicited systemic AEs after each and any injection of a pneumococcal vaccineTime frame: Within 30 days after vaccination
  4. Number of participants reporting serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From day 0 to day 517
  5. Number of Infants (7-11 months of age [MoA]) and toddlers (12-23 MoA): with serotype-specific IgG concentrations for all serotypes included in PCV21Time frame: On day 30 after last vaccination
  6. Number of Children (2-5 years of age [YoA]):with serotype specific OPA titers for all serotypes included in PCV21Time frame: On day 30
  7. Number of Children (2-5 years of age [YoA]):with serotype specific IgG concentrations for all serotypes included in PCV21Time frame: On day 30
  8. Number of Children/adolescents (6-17 YoA):with serotype specific OPA titers for all serotypes included in PCV21Time frame: On day 30

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • Site # 8400008

    Paramount, California

  • Site # 8400024

    Doral, Florida

  • Site # 8400007

    Hialeah, Florida

  • Site # 8400014

    Melbourne, Florida

  • Site # 8400009

    Miami, Florida

  • Site # 8400016

    Miami, Florida

  • Site # 8400021

    Fayetteville, Georgia

  • Site # 8400004

    Union City, Georgia

  • Site # 8400003

    Sioux City, Iowa

  • Site # 8400023

    Erlanger, Kentucky

  • Site # 8400018

    Biloxi, Mississippi

  • Site # 8400012

    Ridgeland, Mississippi

  • Site # 8400002

    Omaha, Nebraska

  • Site #8400010

    Binghamton, New York

  • Site # 8400025

    Rochester, New York

  • Site # 8400001

    Houston, Texas

  • Site # 8400017

    Stephenville, Texas

  • Site # 2330004

    Tartu, Estonia

  • Site # 2330006

    Tallinn, Harju, Estonia

  • Site # 2330007

    Tallinn, Harju, Estonia

  • Site # 2330002

    Tallinn, Harju, Estonia

  • Site # 2330003

    Tallinn, Harju, Estonia

  • Site # 2330001

    Paide, Järvamaa, Estonia

  • Site # 2330005

    Tartu, Tartu, Estonia

  • Site # 6160002

    Bydgoszcz, Poland

  • Site # 6160004

    Bydgoszcz, Poland

  • Site # 6160006

    Kłodzko, Poland

  • Site # 6160001

    Torun, Poland

  • Site # 6160009

    Lodz, Lodskie, Poland

  • Site # 6160007

    Warsaw, Masovian Voivodeship, Poland

  • Site # 6160003

    Częstochowa, Silesian Voivodeship, Poland

  • Site # 7640008

    Bangkok, Thailand

  • Site # 7640006

    Bangkok, Thailand

  • Site # 7640007

    Bangkok, Thailand

  • Site # 7640004

    Chiang Mai, Thailand

  • Site # 7640001

    Pathum Thani, Thailand

  • Site # 7640002

    Hat Yai, Changwat Songkhla, Thailand

  • Site # 7640003

    Mueang Nonthaburi, Chiang Mai, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.